Compare Johnson & Johnson (JNJ) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Johnson & Johnson trades at $261.43 (market cap $618.09B), while Vanguard Dividend Appreciation Index Fund ETF trades at $239.06 (market cap $132.40B). The key difference: Johnson & Johnson is far larger — about 4.7× Vanguard Dividend Appreciation Index Fund ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while Vanguard Dividend Appreciation Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Vanguard Dividend Appreciation Index Fund ETF for 134 Days on average.
| JNJ | VIG | |
|---|---|---|
Market Cap | $618.09B | $132.40B |
Volume | 6,050,983 | 1,287,188 |
Sector | Health | — |
52-Week High | $278.43 | $246.61 |
52-Week Low | $186.00 | $210.70 |
Typical Hold Time | 129 Days | 134 Days |
Enterprise Value | $646.37B | — |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
VIG trades at $239.05, up 0.87% with a bullish technical signal from moving averages. The ETF focuses on dividend growth companies with 10+ years of consecutive dividend increases, offering a lower yield but stronger growth profile compared to peers. Recent quarterly dividend increased 7.5%, though year-to-date growth remains modest at 3.3%.
Outlook remains positive for long-term investors seeking dividend growth and capital appreciation, with the ETF averaging 10% annual returns since inception. Key risks include slower dividend growth rates and exclusion of high-yield stocks by design. The fund's quality focus provides defensive characteristics during market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
